HOUSTON, Nov. 25, 2019 /PRNewswire/ -- Marker
Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications,
today announced that its President and Chief Executive
Officer, Peter L. Hoang, will
present at two upcoming investor conferences.
Conference Details
Piper Jaffray 31st Annual
Healthcare Conference
Date: Tuesday,
December 3, 2019
Time: 1:00 p.m. EST
Location: New York, NY
Evercore ISI 2nd Annual HealthCONx Conference
Date:
Wednesday, December 4, 2019
Time: 11:45 a.m. EST
Location: Boston, MA
Live webcasts of the presentations will be accessible from the
investors section of the company's website at
www.markertherapeutics.com and will be available for replay
following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cell therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
Marker is also advancing a number of innovative peptide and
gene-based immuno-therapeutics for the treatment of metastatic
solid tumors, including the Folate Receptor Alpha program (TPIV200)
for breast cancer and the HER2/neu program (TPIV100/110) for breast
cancer, currently in Phase 2 clinical trials.
To receive future press releases via email, please
visit: https://www.markertherapeutics.com/email-alerts/
Forward-Looking Statement Disclaimer
This release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Statements in this news release concerning the
Company's expectations, plans, business outlook or future
performance, and any other statements concerning assumptions made
or expectations as to any future events, conditions, performance or
other matters, are "forward-looking statements." Forward-looking
statements include statements regarding our intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: our research, development and regulatory
activities and expectations relating to our non-engineered
multi-tumor antigen specific T cell therapies; our TPIV200 and
TPIV100/110 programs; the effectiveness of these programs or the
possible range of application and potential curative effects and
safety in the treatment of diseases; and, the timing and success of
our clinical trials, as well as clinical trials conducted by our
collaborators. Forward-looking statements are by their nature
subject to risks, uncertainties and other factors which could cause
actual results to differ materially from those stated in such
statements. Such risks, uncertainties and factors include, but are
not limited to the risks set forth in the Company's most recent
Form 10-K, 10-Q and other SEC filings which are available through
EDGAR at www.sec.gov. The Company assumes no obligation to update
our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-two-upcoming-investor-conferences-300964069.html
SOURCE Marker Therapeutics, Inc.